Raleigh pharma's stock hits record high amid drug launch
Verona Pharma (Nasdaq: VRNA) is already recording millions of dollars in revenue after launching its lead drug in August ...
FierceBiotech1d
The Column Group's biotech taps Surrozen for lung disease research pact
TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...
American Lung Association3d
Living with COPD
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term lung disease that makes breathing more difficult. COPD tends to get worse over time, and actions you can take can either speed up or slow ...
stocknews3d
3 Biotechnology Stocks With Promising Pipelines
With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.
BioSpace4d
Regeneron Reports Mixed Q3 Sales as Eylea Franchise Remains Under Pressure
Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...
Regeneron: Investors In Panic Mode On Increased Eylea Fears
Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.
Regeneron beats results estimates on demand for eczema treatment, eye drug
U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...
Regeneron Reports Third Quarter 2024 Financial and Operating Results
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. "Regeneron had a strong third quarter marked by 11% ...